Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells

BACKGROUND: Pancreatic cancer (PC) is the fourth most common cause of cancer death. Combination therapies with classical chemotherapeutic agents improved treatment of advanced PC at the cost of a relevant toxicity, but the 5-year survival rate remains below 5%. Consequently, new therapeutic options...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Clin Cancer Res
Main Authors: Veschi, Serena, De Lellis, Laura, Florio, Rosalba, Lanuti, Paola, Massucci, Alberto, Tinari, Nicola, De Tursi, Michele, di Sebastiano, Pierluigi, Marchisio, Marco, Natoli, Clara, Cama, Alessandro
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6151049/
https://ncbi.nlm.nih.gov/pubmed/30241558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-018-0904-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados